Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Arzerra receives approval in Japan
Generation and Characterization of Fully Human Monoclonal Antibodies Against Human Orai1 for Autoimmune Disease.
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Amyloid precursor protein at node of Ranvier modulates nodal formation.
Chondroitin sulfate proteoglycans in the nervous system: inhibitors to repair.
Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats.
Editorial for JNV issue on PML.
Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients.
First NW patient to receive OHSU/VAMC-invented MS drug
Conformational Landscape of N-Glycosylated Peptides Detecting Autoantibodies in Multiple Sclerosis, Revealed by Hamiltonian Replica Exchange.
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.
Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination.
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis.
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.
MHC class I-restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8(+) T cells.
Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Suppression of Murine Experimental Autoimmune Optic Neuritis by Mature Dendritic Cells Transfected with Calcitonin Gene-Related Peptide Gene.
Meralgia paresthetica after subcutaneous injection of glatiramer acetate.
Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.
Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
22nd Meeting of European Neurological Society
Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis.
Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.

Pages